VCD-D Study (AMaRC 16-03)
A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.
The primary purpose of this trial is to assess whether the addition of datatumumab to a velcade, cyclophosphamide and dexamethasone treatment regime will cause an improvement in disease progression free survival.
For more information please visit
Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)
Other (specify below)
Parts of research done:
Literature review, Research proposal, Ethics approval